Genelux Corporation to Participate in Fireside Chat at BTIG’s Virtual Biotechnology Conference 2024
30 July 2024 - 9:00PM
Genelux Corporation (NASDAQ: GNLX), a late clinical-stage
immuno-oncology company, today announced that Thomas Zindrick,
President, CEO and Chairman, will discuss clinical-stage programs,
recent announcements, and upcoming milestones in a fireside chat at
BTIG’s Virtual Biotechnology Conference 2024.
The conversation with Kaveri Pohlman, PhD,
Director and BTIG Biotechnology Analyst, is scheduled to begin at
12:00 p.m. ET on Tuesday, August 6, 2024.
About Genelux
CorporationGenelux is a late clinical-stage
biopharmaceutical company focused on developing a pipeline of
next-generation oncolytic immunotherapies for patients suffering
from aggressive and/or difficult-to-treat solid tumor types. The
Company's most advanced product candidate, Olvi-Vec (olvimulogene
nanivacirepvec), is a proprietary, modified strain of the vaccinia
virus. Olvi-Vec currently is being evaluated in OnPrime/GOG-3076, a
multi-center, randomized, open-label Phase 3 registrational trial
evaluating the efficacy and safety of Olvi-Vec in combination
platinum-doublet + bevacizumab compared with physician's choice of
chemotherapy and bevacizumab in patients with
platinum-resistant/refractory ovarian cancer. The core
of Genelux' discovery and development efforts revolves around
its’ proprietary CHOICE™ platform from which the Company has
developed an extensive library of isolated and engineered oncolytic
vaccinia virus immunotherapeutic product candidates, including
Olvi-Vec. For more information, please visit www.genelux.com
and follow us on Twitter @Genelux_Corp and on LinkedIn.
Investor and Media Contacts
Ankit Bhargava, MDAllele Communications,
LLCgenelux@allelecomms.com
Source: Genelux Corporation
Genelux (NASDAQ:GNLX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Genelux (NASDAQ:GNLX)
Historical Stock Chart
From Sep 2023 to Sep 2024